These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6804016)

  • 21. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.
    al-Alwan NA; al-Kubaisy W; al-Rawaq K
    East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
    Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
    Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy.
    Chrapusta SJ; Giermek J; Pieńkowski T
    Med Sci Monit; 2004 Oct; 10(10):CR577-86. PubMed ID: 15448598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.
    Namer M; Lalanne C; Baulieu EE
    Cancer Res; 1980 May; 40(5):1750-2. PubMed ID: 7371003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
    Ciocca DR; Green S; Elledge RM; Clark GM; Pugh R; Ravdin P; Lew D; Martino S; Osborne CK
    Clin Cancer Res; 1998 May; 4(5):1263-6. PubMed ID: 9607585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoplasmic and nuclear estrogen and progesterone receptors in male breast cancer.
    Pegoraro RJ; Nirmul D; Joubert SM
    Cancer Res; 1982 Nov; 42(11):4812-4. PubMed ID: 7127316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steroid hormone receptors in mammary carcinoma: the effect of tamoxifen.
    Koenders AJ; Beex LV; Geurts-Moespot J; Benraad TJ
    Eur J Cancer (1965); 1980; Suppl 1():63-6. PubMed ID: 7318871
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of malignant breast tumors containing estrogen receptors].
    El'tsina NV
    Vopr Onkol; 1982; 28(4):95-102. PubMed ID: 7046238
    [No Abstract]   [Full Text] [Related]  

  • 30. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen.
    Murphy LC; Niu Y; Snell L; Watson P
    Clin Cancer Res; 2004 Sep; 10(17):5902-6. PubMed ID: 15355923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer.
    de Souza Sales JF; Cabello C; Alvarenga M; Torresan RZ; Duarte GM
    Breast; 2007 Apr; 16(2):197-203. PubMed ID: 17178225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
    Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
    Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of hormoneresponsive breast tumor cells by tamoxifen induced fluorescence.
    Moriquand J; Bartoli MH; Mermet MA; Stage JC; Moriquand CL
    Pathologica; 1985; 77(1049):273-9. PubMed ID: 3831880
    [No Abstract]   [Full Text] [Related]  

  • 34. Reliability of estrogen receptors in predicting response to antiestrogens.
    Valavaara R
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):14-8. PubMed ID: 9165501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
    Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL
    J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
    Pietras RJ; Arboleda J; Reese DM; Wongvipat N; Pegram MD; Ramos L; Gorman CM; Parker MG; Sliwkowski MX; Slamon DJ
    Oncogene; 1995 Jun; 10(12):2435-46. PubMed ID: 7784095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486).
    Milewicz T; Gregoraszczuk EL; Sztefko K; Augustowska K; Krzysiek J; Ryś J
    Growth Horm IGF Res; 2005 Apr; 15(2):140-7. PubMed ID: 15809018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
    Buzdar AU; Vergote I; Sainsbury R
    Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple-negative breast cancer.
    Winkeljohn DL
    Clin J Oncol Nurs; 2008 Dec; 12(6):861-3. PubMed ID: 19064379
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor--positive operable breast cancer.
    Jones LW; Haykowsky M; Pituskin EN; Jendzjowsky NG; Tomczak CR; Haennel RG; Mackey JR
    Oncologist; 2007 Oct; 12(10):1156-64. PubMed ID: 17962609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.